Home › Funds › PSP Research LLC › ACAD
PSP Research LLC position in ACAD
ACADIA PHARMACEUTICALS INC · Health Care
PSP Research LLC reported holding 19,766 shares of ACAD (ACADIA PHARMACEUTICALS INC) in its Q2 2026 13F filing — a position valued at US$500K, representing 0.27% of its reported portfolio and ranking #20 among its reported holdings. PSP Research LLC has disclosed ACAD holdings in 3 of the last 3 reported quarters, going back to Q4 2025.
How PSP Research LLC's ACAD position evolved
PSP Research LLC first disclosed a stake in ACAD in Q4 2025 at 19,766 shares (US$528K). Across 3 filings, PSP Research LLC held the position steady without any share-count change. The most recent filing (Q2 2026) shows 19,766 shares valued at US$500K.
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2025 | 19.77K | $527.95K | New |
| Q1 2026 | 19.77K | $439.99K | Hold |
| Q2 2026 | 19.77K | $500.08K | New |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About ACAD and 13F data
ACAD (ACADIA PHARMACEUTICALS INC) is a Health Care company. 32 other funds we track also report a position in ACAD — the largest reported positions include BAKER BROS. ADVISORS LP (US$1.09B), RTW INVESTMENTS, LP (US$180.8M), Palo Alto Investors LP (US$72.5M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding ACAD
- BAKER BROS. ADVISORS LP 42.91M sh · $1.09B · Q2 2026
- RTW INVESTMENTS, LP 7.14M sh · $180.76M · Q2 2026
- Palo Alto Investors LP 2.86M sh · $72.46M · Q2 2026
- BRAIDWELL LP 1.65M sh · $41.65M · Q2 2026
- Frazier Life Sciences Management, L.P. 1.44M sh · $36.39M · Q2 2026